The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects
about
Grapefruit juice enhances the exposure to oral oxycodoneRole of active metabolites in the use of opioidsUsing molecular similarity to highlight the challenges of routine immunoassay-based drug of abuse/toxicology screening in emergency medicine.Exposure to oral oxycodone is increased by concomitant inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 alone.Different effects of morphine and oxycodone in experimentally evoked hyperalgesia: a human translational study.Effects of aprepitant on the pharmacokinetics of controlled-release oral oxycodone in cancer patients.Pharmacokinetics and ventilatory effects of intravenous oxycodone in postoperative children.Analgesic efficacy of controlled-release oxycodone in postoperative pain.Recent advances in the use of opioids for cancer painContribution to variability in response to opioids.Clinical pharmacology of analgesic medicines in older people: impact of frailty and cognitive impairmentMiconazole oral gel increases exposure to oral oxycodone by inhibition of CYP2D6 and CYP3A4.Influences on the pharmacokinetics of oxycodone: a multicentre cross-sectional study in 439 adult cancer patients.Cancer pain management-current status.Effects of the NK1 antagonist, aprepitant, on response to oral and intranasal oxycodone in prescription opioid abusers.Pharmacodynamic effects of oral oxymorphone: abuse liability, analgesic profile and direct physiologic effects in humans.Comparison of oxycodone and fentanyl for postoperative patient-controlled analgesia after laparoscopic gynecological surgery.Subjective and psychomotor effects of carisoprodol in combination with oxycodone in healthy volunteers.Metabolism of oxycodone in human hepatocytes from different age groups and prediction of hepatic plasma clearance.Can coadministration of oxycodone and morphine produce analgesic synergy in humans? An experimental cold pain studyAn oxycodone conjugate vaccine elicits drug-specific antibodies that reduce oxycodone distribution to brain and hot-plate analgesia.Present-day challenges and future solutions in postoperative pain management: results from PainForum 2014.Separate and combined psychopharmacological effects of alprazolam and oxycodone in healthy volunteers.The treatment of breakthrough pain.Oxycodone: a pharmacological and clinical review.Within-subject comparison of the psychopharmacological profiles of oral oxycodone and oral morphine in non-drug-abusing volunteersDetermination of oxycodone, noroxycodone and oxymorphone by high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry in human matrices: in vivo and in vitro applications.Efficacy of extended-release tramadol for treatment of prescription opioid withdrawal: a two-phase randomized controlled trial.The prescription opioid, oxycodone, does not alter behavioral measures of impulsivity in healthy volunteers.Pediatric palliative care: use of opioids for the management of pain.Pharmacokinetics of intranasal crushed OxyContin and intravenous oxycodone in nondependent prescription opioid abusers.A systematic review of the use of opioid medication for those with moderate to severe cancer pain and renal impairment: a European Palliative Care Research Collaborative opioid guidelines project.Oxycodone for the treatment of postoperative pain.Optimal management of breakthrough cancer pain (BCP).Oxycodone combined with opioid receptor antagonists: efficacy and safety.Cytochrome P450-mediated changes in oxycodone pharmacokinetics/pharmacodynamics and their clinical implications.Pharmacokinetic and pharmacodynamic evaluation of oxycodone and naltrexone for the treatment of chronic lower back pain.Population pharmacokinetics of oxycodone in patients with cancer-related pain.Successful dose finding with sublingual fentanyl tablet: combined results from 2 open-label titration studies.Oxycodone in the long-term treatment of chronic pain related to scleroderma skin ulcers.
P2860
Q28280213-4CE4B9B8-20DC-4F62-9871-F7647695F3C2Q28298981-40C4A5BA-A859-46E4-9F6A-56FA685694B6Q33436079-3344E6A8-0890-46DD-A4AD-EA7568C0AB47Q34019354-FA305A49-7556-4BD0-82DF-B935C18D75B2Q34026235-DA78E5CD-8EE9-4943-BC0B-EA3F1BDB1343Q34046633-388D0533-E004-416A-8E84-028C4A4A46D7Q34346502-7F898611-85CD-490E-8657-8B5446C85609Q34400847-8F8DF4B3-B1A9-4B66-B495-943767B21B14Q34418203-99F90A56-D9EC-4D38-AC33-878E41E78701Q34555917-FB93E895-B343-4B82-B378-E623B4F19E3DQ34608990-F89F4550-A7EF-40EE-B5F2-DD4921575633Q34737242-FF1C2518-52F8-4E31-8CD1-DA7326C93748Q34792547-E39B7E88-FDCE-4999-B88F-9D892E582387Q35079724-0C7B46CB-36BD-4EC5-B598-0F64B5A09435Q35162929-C58BF2E2-BF58-4920-BD8D-E3B18855603EQ35252121-67CCA676-72E9-4797-ADEB-03405FFA268CQ35258483-FC7AD444-7114-4E91-8193-EAE9CBB76273Q35618981-596D375F-1AF9-4AD0-A5B0-51255D763DA4Q35653564-9BBCA5DB-B9DB-4B9E-B058-96BCDFAF9D5BQ35826278-84D726DA-FDCE-4F48-8131-EFFEEE76A94BQ35847661-80060F75-9D9F-4CFB-B4C7-AE459BC5A35AQ36557969-4D8F0B2F-C6E4-4A94-8202-4A44ABDF1227Q36599609-733B51FF-4477-4066-83DC-2C10621C9ECCQ36728954-5337F798-DB72-4521-A7EC-AFDD4BCF8D21Q36831469-0DC5C3D1-FC85-45C5-9EEF-BB986C7AAE1CQ36925954-3680C90C-F71C-4000-AC23-ACDA012ABBD9Q37003866-CCCFFBD4-C91B-4A71-93B6-287551D0FB8DQ37204912-6DFF1841-01BC-4703-9E32-B40AE6B8F667Q37366793-450745B3-EEC2-42D8-8B72-0B9FEA728303Q37419356-F829E448-13CD-4493-A529-3E63CC70BA9EQ37735281-684DA194-E203-4EA5-9DC2-08CC66D33008Q37895002-BF494D64-43EA-4E09-A5C3-719C0895AC10Q38004077-F68B9B66-FE92-41A6-A34E-C0B095869B40Q38069518-DC4B52D8-02E6-428A-9391-101E5C110269Q38093671-DFCBC4C1-3EC1-4FF0-9AA2-8A6597ACF5AAQ38100710-540C70D3-5C43-4E1E-AFFF-838C3C17EDB6Q38851461-C7375C44-9275-4BE9-8477-B2A763ED08EFQ39241949-C2F8FD6A-53F2-48AC-833A-0333B3E7ED65Q39253677-A485B2F6-331A-4814-88A6-8EF502B80F9DQ39286134-2263A8F6-0D11-4DC3-9A0C-37D13BA3F525
P2860
The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects
description
1992 nî lūn-bûn
@nan
1992 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
1992 թվականի հունիսին հրատարակված գիտական հոդված
@hy
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
name
The pharmacokinetics and metab ...... nistration to healthy subjects
@ast
The pharmacokinetics and metab ...... nistration to healthy subjects
@en
The pharmacokinetics and metab ...... nistration to healthy subjects
@nl
type
label
The pharmacokinetics and metab ...... nistration to healthy subjects
@ast
The pharmacokinetics and metab ...... nistration to healthy subjects
@en
The pharmacokinetics and metab ...... nistration to healthy subjects
@nl
prefLabel
The pharmacokinetics and metab ...... nistration to healthy subjects
@ast
The pharmacokinetics and metab ...... nistration to healthy subjects
@en
The pharmacokinetics and metab ...... nistration to healthy subjects
@nl
P2093
P2860
P1476
The pharmacokinetics and metab ...... nistration to healthy subjects
@en
P2093
P2860
P304
P356
10.1111/J.1365-2125.1992.TB04090.X
P407
P577
1992-06-01T00:00:00Z